How to Help Your Patients Save Money on Spinraza (Nusinersen): A Provider's Guide to Savings Programs

Spinraza (nusinersen) is one of the most expensive drugs ever approved. At approximately $125,000 per injection — $750,000 in the first year and $375,000 per year in maintenance — the financial burden on patients and families can be overwhelming even with good insurance. For providers managing SMA patients, proactively addressing financial access is as important as clinical management.

This guide covers every major savings and financial assistance program available for Spinraza in 2026 — and practical strategies for helping every patient access them.

Why Financial Navigation Is a Clinical Priority for SMA Providers

In SMA — particularly infantile-onset SMA Type 1 — treatment delays are directly correlated with worse outcomes. Motor neurons lost before treatment begins cannot be recovered. This means that financial barriers that delay treatment are not merely administrative inconveniences; they are clinical harms.

Integrating financial navigation into your SMA care process — ideally with a dedicated social worker, case manager, or financial navigator — is one of the highest-value investments your practice can make.

Program 1: Biogen SMA360° — The Primary Support Infrastructure

Biogen's SMA360° program is the foundational financial support system for all Spinraza patients. Enroll every patient at the time of diagnosis, regardless of their insurance status. The program provides:

Insurance benefits verification: SMA360° will investigate your patient's insurance coverage for Spinraza, including whether it is covered under medical benefits and what the PA requirements are.

Prior authorization support: The program can assist your office in compiling and submitting PA documentation, and can provide clinical support materials for appeals.

Co-pay assistance (commercial insurance): Commercially insured patients may pay as little as $0 for Spinraza drug costs. Assistance with administration fees may also be available.

Patient assistance (uninsured/underinsured): Qualifying patients without adequate insurance can receive Spinraza at no cost through the patient assistance program.

Bridge program: Eligible patients can receive Spinraza doses at no cost while the PA review is pending, eliminating the most dangerous delay period in newly diagnosed SMA patients.

Contact: 844-477-4672 | spinraza.com. Establish an account with a dedicated SMA360° case manager for your practice if you don't already have one.

Program 2: Medicare Patients — Unique Challenges and Solutions

Spinraza is covered under Medicare Part B (billed as a medical benefit, HCPCS code J2326). However, Medicare patients face unique challenges:

Manufacturer co-pay assistance (SMA360°) is legally prohibited for Medicare beneficiaries due to federal anti-kickback regulations. Do not attempt to enroll Medicare patients in co-pay programs.

Under Medicare Part B, patients are typically responsible for 20% coinsurance after meeting their deductible. For a $125,000 injection, this means $25,000 per dose — devastating out-of-pocket costs.

Medicare Advantage plans vary — some have lower coinsurance or caps; review the patient's specific plan.

Solutions for Medicare patients:

HealthWell Foundation: Nonprofit that provides premium and cost-sharing assistance for Medicare patients with SMA. Visit healthwellfoundation.org.

NORD (National Organization for Rare Disorders): Provides patient assistance grants for Medicare patients with qualifying rare diseases including SMA. Visit rarediseases.org.

Medicare Savings Programs: Qualifying low-income Medicare patients may receive cost-sharing assistance through state Medicare Savings Programs that pay Part B premiums, deductibles, and coinsurance.

Program 3: Medicaid Patients

Most state Medicaid programs cover Spinraza, though coverage criteria and PA requirements vary significantly by state. SMA patients on Medicaid often face minimal out-of-pocket costs but may encounter more restrictive coverage criteria. Key considerations:

PA is typically required and may need renewal more frequently than commercial plans

Quantity limits may apply — Medicaid may have strict limits on number of doses per period

SMA360°'s PA support team can assist with Medicaid submissions in most states

Cure SMA has state-specific Medicaid advocacy experience — contact them for state-specific coverage questions

Program 4: Nonprofit Foundation Assistance

In addition to manufacturer programs, several nonprofit foundations provide independent financial assistance for SMA patients:

Cure SMA (curesma.org): Patient advocacy and financial resource navigation

MDA (mda.org): Neuromuscular disease support and financial resources

Patient Advocate Foundation (patientadvocate.org): Free case management for insurance appeals, co-pay relief, and financial assistance navigation

NORD (rarediseases.org): Patient assistance grants and case management for rare disease patients

Managing the High-Dose Regimen's Financial Implications

The March 2026 FDA-approved High Dose Regimen of Spinraza (50 mg/28 mg) has yet to be fully priced in the U.S. market as of this writing. When prescribing the high-dose regimen, be prepared for:

A separate PA process for the new regimen (separate from the existing 12 mg PA)

Insurance plan formulary updates that may lag behind the FDA approval timeline

Co-pay programs through SMA360° that should cover the new regimen — confirm with the SMA360° team

Building Financial Navigation Into Your Practice

Best practices for SMA centers to proactively manage financial barriers:

Designate a financial navigator or social worker as a core member of the SMA multidisciplinary team

Enroll every patient in SMA360° at the time of diagnosis — before you ever submit the first PA

Create a standardized checklist for PA submission to ensure first-pass approval rates

Track PA expiration dates in your EHR and initiate renewals 4-6 weeks in advance

Maintain relationships with Cure SMA, MDA, NORD, and HealthWell to quickly connect patients with independent resources

How medfinder Supports Provider Practices

For practices managing multiple SMA patients, the logistics of specialty drug access, PA tracking, and financial assistance coordination can strain clinical staff. medfinder for providers is a paid service that helps offload specialty drug access work from your practice — so your team can focus on clinical care while medfinder handles the logistics of finding and coordinating access to specialty medications.

Also see: How to Help Your Patients Find Spinraza In Stock: A Provider's Guide for practical access navigation strategies.